可溶性ST2在冠心病中的研究进展
Research Progress of Soluble ST2 in Coronary Heart Disease
DOI: 10.12677/ACM.2022.123264, PDF,   
作者: 于明霞, 任晓艺：华北理工大学研究生院，河北 唐山；河北北方学院，河北 张家口；张露萍：华北理工大学研究生院，河北 唐山；河北省人民医院心血管内四科，河北 石家庄；刘美霞*：华北理工大学研究生院，河北 唐山
关键词: 可溶性ST2；冠心病；生物标志物；Soluble ST2； Coronary Heart Disease； Biomarkers
摘要: 近年来，可溶性生长刺激表达基因2蛋白(soluble growth stimulation expressed gene 2, sST2)逐渐被列为心衰预后标志物，可反应心肌纤维化程度，有助于心衰患者的危险分层和预后评估。但是目前国内关于sST2与冠心病的研究相对较少，因此本文就可溶性ST2在冠心病中的研究进展进行阐述。
Abstract: In recent years, soluble ST2 (sST2) has gradually been listed as a prognostic marker of heart failure, which can reflect the degree of myocardial fibrosis and contribute to the risk stratification and prognosis evaluation of patients with heart failure. However, there are relatively few studies on sST2 and coronary heart disease in China, so this paper describes the research progress of soluble ST2 in coronary heart disease.
文章引用：于明霞, 张露萍, 任晓艺, 刘美霞. 可溶性ST2在冠心病中的研究进展[J]. 临床医学进展, 2022, 12(3): 1836-1840. https://doi.org/10.12677/ACM.2022.123264

参考文献

[1] Altara, R., Ghali, R., Mallat, Z., Cataliotti, A., Booz, G.W. and Zouein, F.A. (2018) Conflicting Vascular and Metabolic Impact of the IL-33/sST2 Axis. Cardiovascular Research, 114, 1578-1594. [Google Scholar] [CrossRef] [PubMed]
[2] De Vries, M.R. and Quax, P.H. (2016) Plaque Angiogenesis and Its Relation to Inflammation and Atherosclerotic Plaque Destabilization. Current Opinion in Lipidology, 27, 499-506. [Google Scholar] [CrossRef] 
[3] Merino-Merino, A., Gonzalez-Bernal, J., Fernandez-Zoppino, D., Saez-Maleta, R. and Perez-Rivera, J.-A. (2021) The Role of Galectin-3 and ST2 in Cardiology: A Short Review. Biomolecules, 11, Article No. 1167. [Google Scholar] [CrossRef] [PubMed]
[4] Aimo, A., Migliorini, P., Vergaro, G., Franzini, M., Passino, C., Maisel, A., et al. (2018) The IL-33/ST2 Pathway, Inflammation and Atherosclerosis: Trigger and Target? International Journal of Cardiology, 267, 188-192. [Google Scholar] [CrossRef] [PubMed]
[5] Schmitz, J., Owyang, A., Oldham, E., Song Y, Murphy, E., McClanahan, T.K., et al. (2005) IL-33, an Interleukin-1-Like Cytokine That Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity, 23, 479-490. [Google Scholar] [CrossRef] [PubMed]
[6] Vianello, E., Dozio, E., Tacchini, L., Frati, L. and Corsi Romanelli, M.M. (2019) ST2/IL-33 Signaling in Cardiac Fibrosis. The International Journal of Biochemistry & Cell Biology, 116, Article ID: 105619. [Google Scholar] [CrossRef] [PubMed]
[7] Cayrol, C. and Girard, J.P. (2018) Interleukin-33 (IL-33): A Nuclear Cytokine from the IL-1 Family. Immunological Reviews, 281, 154-168. [Google Scholar] [CrossRef] [PubMed]
[8] 杨涛, 邓平, 唐嘉宇, 张玲玲. IL_33及其受体ST2与动脉粥样硬化的研究进展[J]. 广州医药, 2015, 46(2): 95-97.
[9] Miller, A.M., Xu, D., Asquith, D.L., Denby, L., Li, Y., Sattar, N., et al. (2012) IL-33 Reduces the Development of Atherosclerosis. Journal of Experimental Medicine, 209, 2515. [Google Scholar] [CrossRef] 
[10] 孙爱梅, 刘婷, 陈还珍. 可溶性ST2对冠心病的危险分层价值及其与心功能的关系[J]. 中国心血管杂志, 2017, 22(1): 19-23.
[11] Zhang, Y., Fan, Z., Liu, H., Ma, J. and Zhang, M. (2020) Correlation of Plasma Soluble Suppression of Tumorigenicity-2 Level with the Severity and Stability of Coronary Atherosclerosis. Coronary Artery Disease, 31, 628-635. [Google Scholar] [CrossRef] 
[12] Gu, L. and Li, J. (2019) Short-Term and Long-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Acute Coronary Syndrome: A Meta-Analysis. Bioscience Reports, 39, BSR20182441. [Google Scholar] [CrossRef] 
[13] Liu, X., Hu, Y., Huang, W., Zhang, G., Cao, S., Yan, X., et al. (2019) Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI. International Heart Journal, 60, 19-26. [Google Scholar] [CrossRef] [PubMed]
[14] Mzoughi, K., Chouaieb, S., Zairi, I., Fredj, S., Ben Kilani, M., Berriri, S., et al. (2019) Prognostic Value of ST2 in Myocardial Infarction. Tunisie Medicale, 97, 335-343.
[15] 陶俊, 戴雯, 周漫, 李艳. 血清可溶性ST2与冠心病患者肾功能的相关性研究[J]. 微循环学杂志, 2021, 31(3): 22-26+31.
[16] Lobdell, K.W., Parker, D.M., Likosky, D.S., Rezaee, M., Wyler von Ballmoos, M., Alam, S.S., et al. (2018) Preoperative Serum ST2 Level Predicts Acute Kidney Injury after Adult Cardiac Surgery. Journal of Thoracic and Cardiovascular Surgery, 156, 1114-1123.E2. [Google Scholar] [CrossRef] [PubMed]
[17] Marino, R., Magrini, L., Orsini, F., Russo, V., Cardelli, P., Salerno, G., et al. (2017) Comparison between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain. Annals of Laboratory Medicine, 37, 137-146. [Google Scholar] [CrossRef] [PubMed]
[18] 李进, 王卫卫. 血清hs-CRP和sST2与急性冠脉综合征患者病情及预后的相关性[J]. 医学临床研究, 2021, 38(5): 713-716.
[19] 李晓渝, 储岳峰, 周鑫. 急性心肌梗死患者经皮冠状动脉介入治疗后血清sST2、NT-proBNP浓度预测心力衰竭的价值[J]. 岭南心血管病杂志, 2020, 26(2): 138-143.
[20] Kercheva, M., Ryabova, T., Gusakova, A., Suslova, T.E., Ryabov, V., Karpov, R.S. (2019) Serum Soluble ST2 and Adverse Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction. Clinical Medicine Insights, 13, Article ID: 1179546819842804. [Google Scholar] [CrossRef] [PubMed]
[21] Miñana, G., Núñez, J., Bayés-Genís, A., Revuelta-López, E., Ríos-Navarro, C., Núñez, E., et al. (2018) ST2 and Left Ventricular Remodeling after ST-Segment Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Study. International Journal of Cardiology, 270, 336-342. [Google Scholar] [CrossRef] [PubMed]
[22] Aleksova, A., Paldino, A., Beltrami, A.P., Padoan, L., Iacoviello, M., Sinagra, G., et al. (2019) Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome-There is Meat on the Bone. Journal of Clinical Medicine, 8, Article No. 270. [Google Scholar] [CrossRef] [PubMed]
[23] Martínez-Martínez, E., Cachofeiro, V., Rousseau, E., Álvarez, V., Calvier, L., Fernández-Celis, A., et al. (2015) Interleukin-33/ST2 System Attenuates Aldosterone-Induced Adipogenesis and inflammation. Molecular and Cellular Endocrinology, 411, 20-27. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, B., Geng, J., Gao, S.X., Yue, W.W. and Liu, Q. (2018) Eplerenone Modulates Interleukin-33/sST2 Signaling and IL-1beta in Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction. Journal of Interferon & Cytokine Research, 38, 137-144. [Google Scholar] [CrossRef] [PubMed]
[25] Xia, J., Qu, Y., Yin, C. and Xu, D. (2017) Preliminary Study of Beta-Blocker Therapy on Modulation of Interleukin-33/ST2 Signaling during Ventricular Remodeling after Acute Myocardial Infarction. Cardiology Journal, 24, 188-194. [Google Scholar] [CrossRef] 
[26] Feng, Q., Lu, C., Wang, L., Song, L., Li, C. and Uppada, R.C. (2017) Effects of Renal Denervation on Cardiac Oxidative Stress and Local Activity of the Sympathetic Nervous System and Renin-Angiotensin System in Acute Myocardial Infracted Dogs. BMC Cardiovascular Disorders, 17, Article No. 65. [Google Scholar] [CrossRef] [PubMed]
[27] Sharp 3rd, T.E. and Lefer, D.J. (2021) Renal Denervation to Treat Heart Failure. Annual Review of Physiology, 83, 39-58. [Google Scholar] [CrossRef] [PubMed]
[28] Zhao, Y.N., Li, H., Zhao, C. and Liu, G.-H. (2020) ST2 Silencing Aggravates Ventricular Remodeling and Chronic Heart Failure in Rats by Mediating the IL-33/ST2 Axis. Journal of Tissue Engineering and Regenerative Medicine, 14, 1201-1212. [Google Scholar] [CrossRef] [PubMed]
[29] Díez, J. and Bayes-Genis, A. (2017) Compelling Benefit of Soluble Suppression of Tumorigenicity-2 in Post-Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. Journal of the American Heart Association, 6, e007665. [Google Scholar] [CrossRef] 

为你推荐